44 results about "Neuropathy HIV" patented technology

Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies.

Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or Parkinson's disease, comprising the same. The peptides can induce the expression of BDNF in dopamine-reactive human cells, pass easily through the blood-brain barrier thanks to their low molecular weights and are almost free of cytotoxicity. Thus, they are useful in the prevention and treatment of neuropathies such as Alzheimer's disease or Parkinson's disease.

A therapeutic drug for psychoneurotic disorders, which is useful for therapies of psychoneurotic disorders, especially restless legs syndrome is disclosed. The therapeutic drug for psychoneurotic disorders according to the present invention comprises as an effective ingredient an opioid κ receptor agonist compound (excluding pentazocine) such as (−)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloric acid salt.

Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.

Methods and compositions for treating neuropathies.

A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.

The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound.

Methods are provided for relieving pain associated with peripheral neuropathy, by topical application to human skin of a topical composition comprising Hamelia patens extract in combination with a dermatologically-acceptable carrier. According to methods of the invention, the topical composition is applied to human skin at a sufficient concentration and for a sufficient time to relieve pain associated with peripheral neuropathy.

Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity of motion that affect a nerve pathway at more than one locus associated with the disorder to inhibit the disorder. Alternatively or in addition, neuropathy associated with a disorder is treatable by palpating to determine a Keystone nerve essential to the neuropathy, applying pressure to determine a point of maximum discomfort or trigger of increased symptoms to identify a Levin Sign as a locus of initial intervention, and intervening to treat the neuropathy at the location of the Levin Sign by administering a pharmaceutically active agent, internal implanted or external neuro stimulation affecting the nerve pathway to inhibit the neuropathy.

The present invention relates to the use of glucomoringin (GMG) and of the corresponding isothiocyanate derivative glucomoringin des-thioglucoside (GMG-ITC) as modulators of peripheral pain with specific reference to that linked with diabetic peripheral neuropathy and chemotherapy-induced neuropathy.

The invention relates to the fields of neurology, geriatrics and neuropharmacology in biomedicine, and particularly relates to the new medicinal applications of antiepileptic drug tiagabine. The applications disclosed by the invention are based on the pathological features of Parkinson disease and the inhibitory effect of GABA in central nervous system and immune system, and the results of experiments in a neurotoxin-induced mouse model with Parkinson disease show that tiagabine, a gamma-aminobutyric acid transporter antagonist is used for protecting dopaminergic neuron by enhancing the system activity of gamma-aminobutyric acid and inhibiting neuroinflammation, thus having a treatment function on Parkinson disease. Tiagabine can be used for preparing medicines for treating dopaminergic neuron injuries and medicines for treating Parkinson disease.

Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD⁺ in the subject.

The invention provides a kit used for detecting PJVK gene c.887G>A mutation. The existence of the mutant gene in a patient is determined by detection, such that causes and types of the occurrences of neurosensory deafness and auditory neuropathy/auditory neuropathy spectrum disorders are diagnosed. The mutant gene and the detection method can promote clinical implementations of PJVK mutation screening works of patients of neurosensory deafness and auditory neuropathy/auditory neuropathy spectrum disorders. Therefore, a basis is provided for the diagnosis and treatments of patients of neurosensory deafness and auditory neuropathy/auditory neuropathy spectrum disorders.

The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (HSV), and then administering to the human the compound anti-HSV agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (Neurodermatitis, Prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, Alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, Crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, Parkinson's disease, anemia, cytopenia those among the diagnostic criteria.

A method of preventing and/or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder.

Compositions comprising omega 3 fatty acids for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system, as the peripheral nervous system neuropathy and glaucoma.

The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound.

The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

The present disclosure relates to a to a method for treating peripheral neuropathy including diabetic neuropathy. It consists of comprehensive set of pain management medications such as sodium channel blockers, N-methyl-D-aspartate (NMDA) receptor antiagonists, α-2 adrenergic receptor agonists, anti-inflammatory drugs, calcium channel blockers, other classes of medications or their mixtures. The medical compound can be encapsulated in PLGA micro-particles for controlled, sustained release over 2-8 weeks. Once a doctor prescribes a set of pain management medications, the prescribed medication(s) can be administered individually or as their mixtures by a commercial painless or user-friendly micro-needle patch or injection device.

The invention discloses a drug for the intervention treatment of diabetic peripheral neuropathy (DPN). The drug comprises the following effective components in percentage by weight: 45 to 80% of chicken egg yolk, and 5 to 15% of dried rehmannia root. The results of animal experiments show that the provided drug can effectively reduce the blood sugar level of diabetic rats, moreover, the area under the curve (AUC) in the glucose tolerance tests is reduced, and the DPN pain index of diabetic rates is also reduced.

The invention discloses application of recombinant human neurite-promoting factor Neuritin and medicine for treating auditory neuropathy. The researches of the invention discover that the recombinanthuman neurite-promoting factor Neuritin has a curative effect on nerve deafness which is caused by cochlea spiral ganglion cell damage caused by noise damage, medicine damage, aging and the like and does not have evident hair cell damage. The curative mechanism of the recombinant human neurite-promoting factor Neuritin is characterized in that the recombinant human neurite-promoting factor Neuritin can effectively protect spiral ganglion cells, effectively maintain the number and arrangement of nerve fibers and guarantee the effective connection among the hair cells, the nerve fibers and the spiral ganglion cells so as to promote the functions of the spiral ganglion cells, the nerve fibers and the hair cells. Therefore, the recombinant human neurite-promoting factor Neuritin can be used for preparing medicine for treating the nerve deafness caused by cochlea spiral ganglion cell damage.

The present invention relates to an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle for use as an ophthalmic neuroprotector in treating an optic neuropathy or congenital optic atrophy.